At present, one of the most frequently mentioned research papers on ru58841 is the effect of topical ru58841 (Android receiver blocker) combined with minoxidil on hair growth in macaque androgenic alopecia, which can be found on the Internet. It is a comparison between topical ru58841 and oral finasteride for the macaque AGA model. The final result is that 12% of 1mg finasteride hair follicles are transformed into growing hair follicles, while 28% of 5% ru58841 are used externally, It proved that it has great potential for AGA, and later it also has type potential in a mouse model, but there is no report of the human experiment at present.
The principle of ru58841 is different from that of finasteride. Finasteride is 5 α Inhibitors of reductase can reduce the concentration of DHT. Ru58841 is the binding agent of androgen receptor AR, which can avoid the combination of AR and DHT and block the process of AGA.
Ru58841 is only used as research chemicals for research. Many people may find it strange. Why on earth is ru58841 also a drug, but it can not enter the market as a prescription drug like finasteride?
Previously, prostrakan pharmaceutical company once planned to officially produce ru58841, but later gave it up for unknown reasons. It is not clear whether it is the drug or other reasons. But what we know is that prostrakan, the last patented company, is looking for cooperation after the second clinical trial of ru58841. Prostrakan found that although ru58841 is a valuable plan, it is not the top priority. You can see the exact information in Morgan Stanley's report to prostrakan. The interesting thing about this report is that ru58841 is very good compared with the historical data of finasteride. In addition, they believe that the market of ru58841 is "reasonable and moderate", and the market value may reach the US $100 million to US $200 million. There may be special skincare products (Dermatology) companies that will be particularly interested in this.
Perhaps a reasonable assumption is that is not sold because of economic problems. Perhaps no company really wants it to do further clinical trials because the drug will not generate much profit. The reason for these situations may be that finasteride is already on the market. Ru588411 must compete with finasteride, and taking one pill is easier than applying it to the scalp once a day. Another possible factor is that the patent of ru58841 has been in the second clinical trial for a long time. If a company decides to sell it to the market, it has only a short time to make money before other companies start competing and making generic drugs. So perhaps failed because of economic benefits. After all, we all know that the primary goal of pharmaceutical companies is to make money. If they don't see the profit, they will give up the listing plan.
Usage of foreign ru58841 step 1: get ru58841 with a purity of more than 99% step 2: measure just 3 grams of ru58841 and pour it into your 5% minoxidil solution step 3: start shaking the solution so that ru58841 powder can be fully dissolved. This step takes five minutes or more.